SOX2 and cancer: In breast cancer, high transcriptional activation of SOX2, monitored by an SRR2 reporter, has been associated with higher tumorigenic capacity in a small subset of cancer stem cell phenotypes (CD44+/CD24-) in triple-negative breast cancer cell lines and patient samples, showing the potential relevance of SRR2 in tumorigenesis [22,23].